Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct 1;124(7):995-1001.
doi: 10.1016/j.amjcard.2019.07.002. Epub 2019 Jul 15.

Lipid-Lowering Prescription Patterns in Patients With Diabetes Mellitus or Cardiovascular Disease

Alanna M Chamberlain  1 , Sarah S Cohen  2 , Jill M Killian  3 , Keri L Monda  4 , Susan A Weston  3 , Ted Okerson  4
Affiliations

Lipid-Lowering Prescription Patterns in Patients With Diabetes Mellitus or Cardiovascular Disease

Alanna M Chamberlain et al. Am J Cardiol. .

Abstract

The purpose of this study is to describe lipid-lowering therapy (LLT) prescriptions and low-density lipoprotein cholesterol (LDL-C) monitoring in patients with diabetes mellitus (DM) with or without concomitant cardiovascular disease (CVD). Olmsted County, Minnesota residents with a first-ever diagnosis of DM or CVD (ischemic stroke/transient ischemic attack, myocardial infarction, unstable angina pectoris, or revascularization procedure) between 2005 and 2012 were classified as having DM only, CVD only, or CVD + DM. All LLT prescriptions and LDL-C measurements were obtained for 2 years after diagnosis. A total of 4,186, 2,368, and 724 patients had DM, CVD, and CVD + DM, respectively. Rates of LDL-C measurement were 1.31, 1.66, and 1.88 per person-year and 14%, 32%, and 42% of LDL-C measurements were <70 mg/dl in those with DM, CVD, and CVD + DM. Within 3 months after diagnosis, 47%, 71%, and 78% of patients with DM, CVD, and CVD + DM were prescribed LLT. Most prescriptions were for moderate-intensity statins. Under one-fifth of patients with CVD and CVD + DM were prescribed high-intensity statins. Predictors of high-intensity statin prescriptions included male sex, having CVD or CVD + DM, increasing LDL-C, and LDL-C measured more recently (2012 to 2014 vs before 2012). In conclusion, a large proportion of patients at high CVD risk are not adequately treated with LLT. Despite often being considered a risk equivalent, patients with DM have substantially lower rates of LLT prescriptions and lesser controlled LDL-C than those with CVD or CVD + DM.

PubMed Disclaimer

Conflict of interest statement

Declarations of Interest: During the course of this research, Keri L. Monda and Ted Okerson were employees and stockholders of Amgen, Inc. Sarah S. Cohen received research grants from Amgen, Inc. Alanna M. Chamberlain is a Co-Investigator of the Rochester Epidemiology Project (R01 AG034676). All other authors report no conflict of interest.

Figures

Figure 1.
Figure 1.
Overall rates (95% confidence interval) of low-density lipoprotein cholesterol measurements before and after index event in patients with diabetes mellitus, cardiovascular disease, and cardiovascular disease with concomitant diabetes mellitus (panel A). Distribution of low-density lipoprotein cholesterol measurements before and after index event in patients with diabetes mellitus, cardiovascular disease, and cardiovascular disease with concomitant diabetes mellitus (panel B). CVD, cardiovascular disease; DM, diabetes mellitus.
Figure 2.
Figure 2.
Proportion of patients on any lipid-lowering therapy before and after index event in patients with diabetes mellitus, cardiovascular disease, and cardiovascular disease with concomitant diabetes mellitus. CVD, cardiovascular disease; DM, diabetes mellitus.
Figure 3.
Figure 3.
Daily rates of statin use in patients with diabetes mellitus (panel A), cardiovascular disease (panel B), and cardiovascular disease with concomitant diabetes mellitus (panel C). CVD, cardiovascular disease; DM, diabetes mellitus. The daily denominators were adjusted accordingly to account for deaths (n=167, 408, and 152 patients in the diabetes mellitus, cardiovascular disease, and cardiovascular disease + diabetes mellitus groups, respectively) and losses to follow-up (n=165, 41, and 6 patients in the diabetes mellitus, cardiovascular disease, and cardiovascular disease + diabetes mellitus groups, respectively).
Figure 4.
Figure 4.
Predictors of high-intensity statin prescriptions among patients with an available baseline low-density lipoprotein cholesterol measurement (defined as a measure within 1 year prior to 30 days after index) and who were not on a high-intensity statin prior to the baseline low-density lipoprotein cholesterol measurement (n=5670). Hazard ratios are adjusted for all other variables in the figure. Low-density lipoprotein cholesterol and year of low-density lipoprotein cholesterol measurement were modeled as time-dependent variables. CHF, chronic heart failure; CI, confidence interval; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; DM, diabetes mellitus; HR, hazard ratio; LDL-C, low-density lipoprotein cholesterol.
See this image and copyright information in PMC

References

    1. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jimenez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation 2017;135:e146–e603. - PMC - PubMed
    1. Karalis DG, Subramanya RD, Hessen SE, Liu L, Victor MF. Achieving optimal lipid goals in patients with coronary artery disease. Am J Cardiol 2011;107:886–890. - PubMed
    1. Rodriguez F, Olufade T, Heithoff K, Friedman HS, Navaratnam P, Foody JM. Frequency of high-risk patients not receiving high-potency statin (from a large managed care database). Am J Cardiol 2015;115:190–195. - PubMed
    1. Toth PP, Foody JM, Tomassini JE, Sajjan SG, Ramey DR, Neff DR, Tershakovec AM, Hu XH, Tunceli K. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease. J Clin Lipidol 2014;8:107–116. - PubMed
    1. Bittner V, Deng L, Rosenson RS, Taylor B, Glasser SP, Kent ST, Farkouh ME, Muntner P. Trends in the use of nonstatin lipid-lowering therapy among patients with coronary heart disease: a retrospective cohort study in the Medicare population 2007 to 2011. J Am Coll Cardiol 2015;66:1864–1872. - PubMed

Publication types

Substances